Targeting antigen-specific T cells by genetically engineered antigen presenting cells A strategy for specific immunotherapy of autoimmune disease

[1]  E. Gilboa,et al.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.

[2]  K. Mcintosh,et al.  How subtle differences in MHC class II affect the severity of experimental myasthenia gravis. , 1998, Clinical immunology and immunopathology.

[3]  R. Siliciano,et al.  The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking Pathway* , 1997, The Journal of Biological Chemistry.

[4]  Craig B. Thompson,et al.  Hierarchical Control of Lymphocyte Survival , 1996, Science.

[5]  D. Drachman.  Immunotherapy in neuromuscular disorders: Current and future strategies , 1996, Muscle & nerve.

[6]  P. Howley,et al.  A vaccinia virus transfer vector using a GUS reporter gene inserted into the I4L locus. , 1996, Gene.

[7]  A. Abbas,et al.  The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. , 1996, Immunity.

[8]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[9]  Kathleen R. Cho,et al.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Linsley,et al.  Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. , 1995, Cellular immunology.

[11]  R. Siliciano,et al.  Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. , 1995, Journal of immunology.

[12]  T. Yokota,et al.  Expression of the Fas ligand in cells of T cell lineage. , 1995, Journal of immunology.

[13]  I. Mellman,et al.  Lonely MHC molecules seeking immunogenic peptides for meaningful relationships. , 1995, Current opinion in cell biology.

[14]  F. Ramsdell,et al.  Fas transduces activation signals in normal human T lymphocytes , 1993, The Journal of experimental medicine.

[15]  N. Brot,et al.  The Fas protein is expressed at high levels on CD4+CD8+ thymocytes and activated mature lymphocytes in normal mice but not in the lupus-prone strain, MRL lpr/lpr. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[17]  L. Moiola,et al.  T‐Helper Epitopes on Human Nicotinic Acetylcholine Receptor in Myasthenia Gravis a , 1993, Annals of the New York Academy of Sciences.

[18]  Brian Salmons,et al.  Targeting of retroviral vectors for gene therapy. , 1993, Human gene therapy.

[19]  F. Guarnieri,et al.  The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. , 1993, The Journal of biological chemistry.

[20]  Stephen W. Martin,et al.  Specific immunotherapeutic strategy for myasthenia gravis: targeted antigen-presenting cells , 1992, Journal of Neuroimmunology.

[21]  J. Lindstrom,et al.  T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: Heterogeneity of antigenic sites on the α‐subunit , 1992, Annals of neurology.

[22]  P. Thompson,et al.  Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. , 1991, Journal of immunology.

[23]  S. Fuchs,et al.  T-cell antigenic sites involved in myasthenia gravis: correlations with antibody titre and disease severity. , 1991, Journal of autoimmunity.

[24]  L. Balcer,et al.  Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies , 1991, Journal of Neuroimmunology.

[25]  M. Oshima,et al.  Autoimmune T cell recognition of human acetylcholine receptor: the sites of T cell recognition in myasthenia gravis on the extracellular part of the α subunit , 1990, European journal of immunology.

[26]  A. Steck,et al.  Immunological heterogeneity of autoreactive T lymphocytes against the nicotinic acetylcholine receptor in myasthenic patients , 1990, European journal of immunology.

[27]  J. Howard,et al.  Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patients. , 1990, Journal of immunology.

[28]  K. Mcintosh,et al.  Antigen-specific suppressor macrophages induced by culture with cyclosporine A plus acetylcholine receptor , 1989, Journal of Neuroimmunology.

[29]  J. Rothbard,et al.  T-cell reactivity in myasthenia gravis. , 1989, Journal of autoimmunity.

[30]  J. Rothbard,et al.  In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. , 1988, The Journal of clinical investigation.

[31]  J. W. Chen,et al.  Isolation and sequencing of a cDNA clone encoding lysosomal membrane glycoprotein mouse LAMP-1. Sequence similarity to proteins bearing onco-differentiation antigens. , 1988, The Journal of biological chemistry.

[32]  R. Hohlfeld,et al.  Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis. , 1988, The Journal of clinical investigation.

[33]  H. Paulson,et al.  Genetic reconstitution of functional acetylcholine receptor channels in mouse fibroblasts. , 1987, Science.

[34]  T. Yeh,et al.  Influence of T cell specificity on the heterogeneity and disease-causing capability of antibody against the acetylcholine receptor , 1987, Journal of Neuroimmunology.

[35]  R. Hohlfeld,et al.  Acetylcholine Receptor‐Specific Human T‐Lymphocyte Lines a , 1987, Annals of the New York Academy of Sciences.

[36]  T. Claudio.  Stable expression of transfected Torpedo acetylcholine receptor alpha subunits in mouse fibroblast L cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[38]  D. Richman,et al.  Cellular immunity to acetylcholine receptor in myasthenia gravis , 1979, Neurology.

[39]  D H Sachs,et al.  Establishment and characterization of BALB/c lymphoma lines with B cell properties. , 1979, Journal of immunology.

[40]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Pestronk,et al.  Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. , 1977, The New England journal of medicine.

[42]  J. Lindstrom,et al.  EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS: CELLULAR AND HUMORAL IMMUNE RESPONSES * , 1976, Annals of the New York Academy of Sciences.

[43]  A. Eldefrawi,et al.  Purification and molecular properties of the acetylcholine receptor from Torpedo electroplax. , 1973, Archives of biochemistry and biophysics.